12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ravicti glycerol phenylbutyrate regulatory update

FDA extended the PDUFA date by 3 months for an NDA from Hyperion for Ravicti glycerol phenylbutyrate for the management of chronic urea cycle disorders in patients >=6 years of age. The new date is...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >